JACC: CardioOncology December 01, 2020 | Vol. 2 No. 5 – Table of Contents of this issue
ARTICLES IN THIS ISSUE (open access):
- PRIMERS IN CARDIO-ONCOLOGY: Strain Imaging in Cardio-Oncology – Jennifer E. Liu, Marielle Scherrer-Crosbie, et. al.
- ORIGINAL RESEARCH: Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors – Marie-A Chaix, Seema Mital, et. al.
- EDITORIAL COMMENT: Harnessing Genomics to Predict and Prevent Anthracycline-Associated Cardiotoxicity – Yadav Sapkota
- ORIGINAL RESEARCH: Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure: A Nationwide Readmissions Database Study – Sameer Arora, Ambarish Pandey, et. al.
- EDITORIAL COMMENT: Cardiac Amyloidosis: More Than a Needle in a Haystack – Karen E. Joynt Maddox and Kathleen W. Zhang
- ORIGINAL RESEARCH: Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation – Graham Lohrmann, Deepa M. Gopal, et. al.
- EDITORIAL COMMENT: Atrial Involvement in Cardiac Amyloidosis: Beyond Dilatation – Marianna Fontana, Ana Martinez-Naharro, et. al.
- ORIGINAL RESEARCH: Impact of Cancer in Patients Undergoing Transcatheter Aortic Valve Replacement: A Single-Center Study – Alexander Lind, Raluca I. Mincu, et. al.
- EDITORIAL COMMENT: Cancer and TAVR: Reassuring Data, But Individualized and Shared Decision-Making Still Required – Brian R. Lindman
- ORIGINAL RESEARCH: Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter – Michael G. Fradley, Kevin E. Kip, et. al.
- EDITORIAL COMMENT: Anticoagulation in Cancer Patients With Atrial Fibrillation or Atrial Flutter: Are There Gaps in Care? – Andrea M. Russo
- ORIGINAL RESEARCH: Lymphoma Severity and Type Are Associated With Aortic FDG Uptake by 18F-FDG PET/CT Imaging – Charalambos V. Vlachopoulos, Constantinos D. Anagnostopoulos, et. al.
- EDITORIAL COMMENT: Aortic FDG Uptake in Patients With Cancer: An Imaging Biomarker of Susceptibility? – Sanjay Divakaran, Marcelo F. Di Carli, et. al.
- ORIGINAL RESEARCH: Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity – Nabil E. Boutagy, Albert J. Sinusas, et. al.
- EDITORIAL COMMENT: Angiotensin Receptor-Neprilysin Inhibition for Doxorubicin-Mediated Cardiotoxicity: Time for a Paradigm Shift – Virginia S. Hahn and Kavita Sharma
- HOW TO: Cardiac Biomarkers During Cancer Therapy: Practical Applications for Cardio-Oncology – Jose A. Alvarez-Cardona, Daniel J. Lenihan, et. al.
- VIEWPOINT: Implementation of Cardio-Oncology Training for Cardiology Fellows – Mirela Tuzovic, Eiman Jahangir, et. al.
- CLINICAL CASE CHALLENGES: Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression – Shiying Liu, Paaladinesh Thavendiranathan, et. al.
- CLINICAL CASE CHALLENGES: Early T Cell Precursor Leukemia Presenting With Superior Vena Cava Syndrome and Cardiac Tamponade – Krishna Santosh Vemuri, Manoj Kumar Rohit, et. al.
- CLINICAL CASE CHALLENGES: Sinus Arrest and Cardiogenic Shock Precipitated by Immune Checkpoint Inhibitors – Kris Kumar, Ahmad Masri, et. al.
- INTERNATIONAL PERSPECTIVES: Cardio-Oncology in Japan: The Rapidly Rising Sun – Toru Oka, Issei Komuro, et. al.
- LEADERSHIP PAGE: Harmonization of Cardiovascular and Oncology and the Blossoming of Cardio-Oncology in Japan – Issei Komuro and Chikashi Ishioka
- EDITOR’S PAGE: A Lift: A Recommended Necessity in 2020 – Bonnie Ky